371 results on '"Shan, Jianqin"'
Search Results
52. Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
53. Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model
54. Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index
55. Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML)
56. Seven-Year Follow-up Data on Sequential Prospective Trials of Imatinib 400mg Vs 800mg Daily Schedule for Front-Line Treatment of Chronic Myeloid Leukemia (CML).
57. Analysis of Outcomes In Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia (CML) Treated with Upfront Tyrosine Kinase Inhibitors (TKI)
58. Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.
59. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia
60. DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
61. Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
62. Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
63. Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.
64. Current Leukemia Free Survival After Tyrosine Kinase Inhibitor (TKI) for Chronic Myeloid Leukemia (CML): A New Method That Accounts for Restoring Response with Sequential TKI.
65. A Prognostic Model of Therapy-Related Myelodysplastic syndrome .
66. Causes of Death for Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Imatinib.
67. Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response
68. Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure.
69. Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP)
70. Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS)
71. Significance of Rising Levels of Minimal Residual Disease in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+ CML) in Complete Cytogenetic Response (CGCR)
72. Patients with Chronic Myeloid Leukemia with Variant Philadelphia Chromosome (Ph) Translocations Have a Similar Outcome as Those with Classic Ph When Treated with Imatinib or 2nd Generation TKI
73. The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS?.
74. Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen.
75. Interferon Therapy Is Predictive Factor for Improved Survival in Patients with Essential Thrombocythemia (ET).
76. Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).
77. High-Dose (HD) Imatinib Provides Better Responses in Patients with Untreated Early Chronic Phase (CP) CML.
78. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
79. Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP).
80. Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.
81. Long-Term Follow-Up Results of the Combination of Topotecan and Cytarabine and Other Intensive Chemotherapy Regimens in Myelodysplastic Syndrome.
82. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy
83. Significance of Marrow Fibrosis in Chronic Phase Chronic Myelogenous Leukemia (CML) Post Interferon-A Failure Treated with Imatinib Mesylate Therapy.
84. Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib.
85. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia
86. Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
87. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-? regimens for early chronic phase
88. Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis
89. Simultaneous homoharringtonine and interferon-α in the treatment of patients with chronic-phase chronic myelogenous leukemia
90. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: An international oncology study group (IOSG) phase II protocol
91. A Prospective Randomized Study of Alpha-2b Interferon plus Hydroxyurea or Cytarabine for Patients with Early Chronic Phase Chronic Myelogenous Leukemia: The International Oncology Study Group CML1 Study
92. A Prospective Randomized Study of Chop Versus Chop Plus Alpha-2B Interferon in Patients with Intermediate and High Grade Non-Hodgkin's Lymphoma: The International Oncology Study Group NHL1 Study
93. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
94. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in early chronic phase
95. Patients with Chronic Myeloid Leukemia with Variant Philadelphia Chromosome (Ph) Translocations Have a Similar Outcome as Those with Classic Ph When Treated with Imatinib or 2ndGeneration TKI
96. Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
97. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
98. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
99. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
100. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.